LXEO vs TMUS · $147.7M cap vs P/E 19, rev $22.79B
Lexeo Therapeutics, Inc. Common Stock (LXEO) versus T-Mobile US Inc (TMUS) — a side-by-side from cached financials, not a winner call.
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
T-Mobile US Inc (TMUS) is a telecom services company listed on NASDAQ. It is led by Mike Sievert.
LXEO does not have a complete income-statement cache yet.
Latest reported TMUS revenue for 2026-06-30 was $22.79B. Net income was $3.24B. Revenue was down 1.4% from 2026-03-31 to 2026-06-30. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
LXEO currently screens at market cap $147.7M. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
Not investment advice. Open the LXEO and TMUS stock pages for the full models.
Not investment advice.